Ultragenyx Pharmaceutical (NASDAQ: RARE)
Ultragenyx Pharmaceutical Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Ultragenyx Pharmaceutical Company Info
Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.
News & Analysis
Why Ultragenyx Pharmaceutical Stock Is Cratering Today
Shareholders aren't happy with the biotech's decision to acquire an early-stage asset for Angelman syndrome.
Why Ultragenyx Pharmaceutical Stock Surged 23.4% Today
A promising clinical trial update has investors increasingly optimistic about the company's pipeline.
Why Stryker, Ultragenyx Pharmaceutical, and La-Z-Boy Slumped Today
These stocks helped put downward pressure on the market. Find out why.
Why Ultragenyx Pharmaceutical Stock Is Sinking Today
Ultragenyx's shares are reeling after the company's experimental drug for muscle-wasting disease fails in a late-stage study.
Why Ultragenyx Pharmaceutical Stock Is Spiking Today
The drugmaker appears to have a potential blockbuster on its hands.
Why Ultragenyx Pharmaceuticals Stock Skyrocketed in 2015
A slew of positive clinical data sends shares higher.
Hillary Clinton's $40 Billion Tweet Breaks Biotech Stocks -- Which 3 Got Hit Hardest?
Clinton jumps into the drug-pricing fray, leading investors in rare-disease drug developers to panic.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.